InBioNET Submits Market Registration for Human Recombinant Interleukin-2

Published: 2005-02-01 06:55:00

Updated: 2005-02-01 06:55:00

Upon completion of the domestic phase II clinical trial of interleukin-2 (product name: Geneleukin), a biopharmaceutical anticancer agent, InBioNET Inc. announced last week that it has submitted a market registration request for Geneleukin to the Korea Food and Drug Administration (KFDA).

Acco...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK